The Spectrum of Myocardial Ischemia

The Paradigm of Acute Coronary Syndromes
  • Christopher P. Cannon
  • Eugene Braunwald
Part of the Contemporary Cardiology book series (CONCARD)


Traditionally, ischemic heart disease has been divided into several separate syndromes: stable coronary artery disease, unstable angina (1,2), non-Q-wave myocardial infarction (MI), and Q-wave MI. However, the recent understanding of the conversion of a stable atherosclerotic lesion to a plaque rupture with thrombosis has provided a unifying hypothesis for the etiology of acute coronary syndromes (3–7). The concept of myocardial ischemia as a spectrum provides a framework for understanding the pathogenesis, clinical features, treatment, and outcome of patients (Fig. 1).


Acute Coronary Syndrome Acute Myocardial Infarction Unstable Angina Thrombolytic Therapy Plaque Rupture 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Braunwald E. Unstable angina: a classification. Circulation 1989; 80: 410–414.PubMedGoogle Scholar
  2. 2.
    Conti CR, Brawley RK, Griffith LSC, Pitt B, Humphries JO, Gott VL, et al. Unstable angina pectoris: morbidity and mortality in 57 consecutive patients evaluated angiographically. Am J Cardiol 1973; 32: 745–750.PubMedGoogle Scholar
  3. 3.
    Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213–1220.PubMedGoogle Scholar
  4. 4.
    Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathophysiology of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326: 242–250, 310–18.Google Scholar
  5. 5.
    Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/ or sudden death. Circulation 1985; 71: 699–708.PubMedGoogle Scholar
  6. 6.
    Willerson JT, Golino P, Eidt J, Campbell WB, Buja M. Platelet mediators and unstable coronary artery disease. Circulation 1989; 80: 198–205.PubMedGoogle Scholar
  7. 7.
    Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657–671.PubMedGoogle Scholar
  8. 8.
    Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–322.Google Scholar
  9. 9.
    The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Circulation 1994; 89: 1545–1556.Google Scholar
  10. 10.
    Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley KM, et al. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10. Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD,1994.Google Scholar
  11. 11.
    DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897–902.PubMedGoogle Scholar
  12. 12.
    TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial; phase I findings. N Engl J Med 1985; 312: 932–936.Google Scholar
  13. 13.
    DeWood MA, Stifter WF, Simpson CS, Spores J, Eugster GS, Judge TP, et al. Coronary arteriographic findings soon after non-Q wave myocardial infarction. N Engl J Med 1986; 315: 417–423.PubMedGoogle Scholar
  14. 14.
    The TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) trial. Circulation 1993; 87: 38–52.Google Scholar
  15. 15.
    Gibbons RJ, Christian TF, Hopfenspirger M, Hodge DO, Bailey KR. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: implications for the design of randomized trials of acute interventions. J Am Coll Cardiol 1994; 24: 616–623.PubMedGoogle Scholar
  16. 16.
    Chester MR, Chen L, Kaski JC. Angiographic evidence for frequent “silent” plaque disruption in patients with stable angina (abstract). J Am Coll Cardiol 1995;Special Issue:428A.Google Scholar
  17. 17.
    Mark DB, Nelson CL, Califf RM, Harrell FE Jr, Lee KL, Jones RH, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 1994; 89: 2015–2025.PubMedGoogle Scholar
  18. 18.
    Webster MWI, Chesebro JH, Smith HC, Frye RL, Holmes DR, Reeder GR, et al. Myocardial infarction and coronary artery occlusion: a prospective 5-year angiographic study (abstract). J Am Coll Cardiol 1990; 15: 218A.Google Scholar
  19. 19.
    Davies MJ. The composition of coronary-artery plaques. N Engl J Med 1997; 336: 1312–1314.PubMedGoogle Scholar
  20. 20.
    Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gertenblith G. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med 1986; 1986: 1214–1219.Google Scholar
  21. 21.
    Rocco MB, Nabel EG, Campbell S, Goldman L, Barry J, Mead K, et al. Prognostic importance of myocardial ischemia detected by ambulatory monitoring in patients with coronary artery disease. Circulation 1988; 78: 877–884.PubMedGoogle Scholar
  22. 22.
    Fung AY, Jue J, Thompson CR, Davies C, Schreiber WE. Diagnosis of microinfarction in acute ischemic syndromes is of prognostic value (abstract). J Am Coll Cardiol 1994;Special Issue:316A.Google Scholar
  23. 23.
    Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L, et al. The prognostic value of troponin T in unstable angina. N Engl J Med 1992; 327: 146–150.PubMedGoogle Scholar
  24. 24.
    Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342–1349.PubMedGoogle Scholar
  25. 25.
    Eisenberg MS, Horwood BT, Cummins RO, Reynolds-Haertle R, Hearne TR. Cardiac arrest and resuscitation: a tale of 29 cities. Ann Emerg Med 1990; 19: 179–186.PubMedGoogle Scholar
  26. 26.
    Cannon CP. Prehospital management of acute myocardial infarction. In: Verstraete M, Fuster V, Topol EJ, eds: Cardiovascular Thrombosis: Thrombocardiology. Lippincott-Raven, Philadelphia, in press.Google Scholar
  27. 27.
    National Heart Attack Alert Program Coordinating Committee-60 Minutes to Treatment Working Group. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994; 23: 311–329.Google Scholar
  28. 28.
    National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. 9–1–1: rapid identification and treatment of acute myocardial infarction. Am J Emer Med 1995;13:188–195.Google Scholar
  29. 29.
    National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. Staffing and equipping emergency medical services systems: rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995; 13: 58–65.Google Scholar
  30. 30.
    National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. Emergency medical dispatching: rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995; 13: 67–73.Google Scholar
  31. 31.
    Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish D, Yeung AC, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 491–497.PubMedGoogle Scholar
  32. 32.
    Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844–2850.PubMedGoogle Scholar
  33. 33.
    Moreno PR, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, Mehran R, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94: 3090–3097.PubMedGoogle Scholar
  34. 34.
    Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090–1094.PubMedGoogle Scholar
  35. 35.
    Cannon CP, Ault K, Mitchell J, McCabe CH, Braunwald E. P-selectin in patients post acute coronary syndromes treated with sibrafiban, an oral IIb/IIIa antagonist: results from TIMI 12 (abstract). Circulation 1997; 96 (suppl. I): I-169.Google Scholar
  36. 36.
    Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61–68.PubMedGoogle Scholar
  37. 37.
    Becker RC, Tracy RP, Bovill EG, Corrao JM, Baker S, Ball SP, et al. Surface 12-lead electrocardiogram findings and plasma markers of thrombin activity and generation in patients with myocardial ischemia at rest. J Thromb Thrombol 1994; 1: 101–107.Google Scholar
  38. 38.
    Davies MJ, Thomas A. Plaque fissuring-the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985; 53: 363–373.PubMedGoogle Scholar
  39. 39.
    Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1998; 92: 1565–1569.Google Scholar
  40. 40.
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979.PubMedGoogle Scholar
  41. 41.
    Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol 1990; 65: 168–172.PubMedGoogle Scholar
  42. 42.
    Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417–424.PubMedGoogle Scholar
  43. 43.
    Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462–466.Google Scholar
  44. 44.
    Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998; 31: 1460–1465.PubMedGoogle Scholar
  45. 45.
    Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniaespecific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993; 87: 1130–1134.PubMedGoogle Scholar
  46. 46.
    Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983–986.PubMedGoogle Scholar
  47. 47.
    Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Dating JR. Association of prior infection with Chlamydia pneumoniae and angiographically deomonstrated coronary artery disease. JAMA 1992; 268: 68–72.PubMedGoogle Scholar
  48. 48.
    Blasi F, Cosentini R, Raccanelli R, Massari FM, Arosio C, Tarsia P, et al. A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. Chest 1997; 112: 309–312.PubMedGoogle Scholar
  49. 49.
    Danesh J, Collins R, Peto R. Chronic infection and coronary heart disease: is there a link? Lancet 1997; 350: 430–436.PubMedGoogle Scholar
  50. 50.
    Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. An assessment of the evidence and need for future research. Circulation 1997; 96: 4095–4103.PubMedGoogle Scholar
  51. 51.
    Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study Group. Randomised trial of roxithromycin in non-Q wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404–407.PubMedGoogle Scholar
  52. 52.
    Gupta S, Leathan EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404–407.PubMedGoogle Scholar
  53. 53.
    Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315: 913–919.PubMedGoogle Scholar
  54. 54.
    Brunelli C, Spallarossa P, Ghigliotta G, Ianetti M, Caponnetto S. Thrombosis in refractory unstable angina. Am J Cardiol 1991; 68: 110B–118B.PubMedGoogle Scholar
  55. 55.
    Uchida Y, Fujimori Y, Hirose J, Oshima T. Percutaneous coronary angioscopy. Jpn Heart J 1992; 33: 271–294.PubMedGoogle Scholar
  56. 56.
    Mizuno K, Satumo K, Miyamoto A, Arakawa E, Shibuya T, Axai T, et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326: 287–291.PubMedGoogle Scholar
  57. 57.
    Sullivan E, Kearney M, Isner JM, Topol EJ, Losordo DW. Pathology of unstable angina: analysis of biopsies obtained by directional coronary atherectomy. J Thromb Thrombolysis 1994; I: 63–71.Google Scholar
  58. 58.
    Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986; 7: 472–478.PubMedGoogle Scholar
  59. 59.
    Ambrose JA, Hjemdahl-Mouser CE, Borneo S, Gorlin R, Fuster V. Angiographie demonstration of a common link between unstable angina and non-Q-wave myocardial infarction. Am J Cardiol 1988; 61: 244–247.PubMedGoogle Scholar
  60. 60.
    Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983–989.PubMedGoogle Scholar
  61. 61.
    Theroux P, Latour JG, Leger-Gautier C, Delaria J. Fibrinopeptide A and platelet factor four levels in unstable angina. Circulation 1987; 75: 156–162.PubMedGoogle Scholar
  62. 62.
    Robertson RM, Robertson D, Roberts LJ, Maas RL, Fitzgerald GA, Friesinger GC, et al. Thromboxane A2 in vasotonic angina pectoris. N Engl J Med 1981; 304: 998–1003.PubMedGoogle Scholar
  63. 63.
    Alexopoloulos D, Ambrose JA, Stump D, Borrico S, Gorlin R, Deshmunk P, et al. Thrombosis-related markers in unstable angina. J Am Coll Cardiol 1991; 17: 866–871.Google Scholar
  64. 64.
    Hirsch PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304: 685–691.Google Scholar
  65. 65.
    van der Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina complex coronary lesion morphology. Circulation 1989; 79: 116–124.PubMedGoogle Scholar
  66. 66.
    Becker RC, Tracy RP, Bovill EG, Mann KG, Ault K, for the TIMI-III Thrombosis and Anticoagulation Study Group. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. Coronary Art Dis 1994; 5: 339–345.Google Scholar
  67. 67.
    Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396–403.PubMedGoogle Scholar
  68. 68.
    Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985; 313: 1369–1375.PubMedGoogle Scholar
  69. 69.
    Theroux P, Ouimet H, McCans J, Latour J-G, Joly G, Levy G, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988; 319: 1105–1111.PubMedGoogle Scholar
  70. 70.
    The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–830.Google Scholar
  71. 71.
    Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 2045–2048.PubMedGoogle Scholar
  72. 72.
    Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation 1994; 89: 81–88.PubMedGoogle Scholar
  73. 73.
    Oler A, Whooley MA, Oler J, Grady D. Adding heparin to asprin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 811–815.PubMedGoogle Scholar
  74. 74.
    FRISC Study Group. Low molecular weight heparin (Fragmin) during instability in coronary artery disease (FRISC). Lancet 1996; 347: 561–568.Google Scholar
  75. 75.
    Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, et al. Comparison of low-molecularweight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Dtudy (FRIC). Circulation 1997; 96: 61–68.PubMedGoogle Scholar
  76. 76.
    Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, et al. A comparison of lowmolecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447–452.PubMedGoogle Scholar
  77. 77.
    The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/ IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497.Google Scholar
  78. 78.
    The Platelet Receptor Inhibition for Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498–1505.Google Scholar
  79. 79.
    The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein lib/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: a randomized, placebo-controlled clinical trial. N Engl J Med 1998; 339: 417–423.Google Scholar
  80. 80.
    Mazzoli S, Tofani N, Fantini A, Semplici R, Bandini F, Salvi A, et al. Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up. Am Heart J 1998; 135: 15–20.PubMedGoogle Scholar
  81. 81.
    Becker RC, Bovill EG, Corrao JM, Ball SP, Ault K, Mann K, et al. Platelet activation determined by flow cytometry persists despite antithrombotic therapy in patients with unstable angina and non-Q wave myocardial infarction. J Thromb Thrombolysis 1994; 1: 95–100.PubMedGoogle Scholar
  82. 82.
    Becker RC, Bovill EG, Corrao JM, Ball SP, Ault K, Mann KG, et al. Dynamic nature of thrombin generation, fibrin formation, and platelet activation in unstable angina and non-Q-wave myocardial infarction. J Thromb Thrombol 1995; 2: 57–64.Google Scholar
  83. 83.
    Trip MD, Manger Cats V, can Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549–1554.PubMedGoogle Scholar
  84. 84.
    Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514–1518.PubMedGoogle Scholar
  85. 85.
    Van Belle E, Lablanche J-M, Bauters C, Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction. Natural history and the effect of thrombolysis. Circulation 1998; 97: 26–33.PubMedGoogle Scholar
  86. 86.
    Inoue K, Ochiai H, Kuwaki K. The mechanism of reocclusion after successful coronary thrombolysis as validated by percutaneous angioscopy (abstract). J Am Coll Cardiol 1994; 13A.Google Scholar
  87. 87.
    Braunwald E. The open-artery theory is alive and well-again. N Engl J Med 1993; 329: 1650–1652.PubMedGoogle Scholar
  88. 88.
    Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? Circulation 1989; 79: 441–444.PubMedGoogle Scholar
  89. 89.
    Gruppo Italiano per to Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–401.Google Scholar
  90. 90.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–360.Google Scholar
  91. 91.
    Reimer KA, Lowe JE, Rasmussen NM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786–794.PubMedGoogle Scholar
  92. 92.
    Rentrop KP, Blanke H, Karsch KR, Kreuzer H. Initial experience with transluminal recanalization of the recently occluded infarct-related coronary artery in acute myocardial infarction. Comparison with conventionally treated patients. Clin Cardiol 1979; 2: 92–105.PubMedGoogle Scholar
  93. 93.
    Ganz W, Buchbinder N, Marcus H, Mondkar A, Maddahi J, Charuzi Y, et al. Intracoronary thrombolysis in evolving myocardial infarction. Am Heart J 1981; 101: 4–13.PubMedGoogle Scholar
  94. 94.
    Cannon CP, Braunwald E. GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol 1994; 49: 1–8.PubMedGoogle Scholar
  95. 95.
    Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 1995; 91: 1923–1928.PubMedGoogle Scholar
  96. 96.
    Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombol 1994; 1: 27–34.Google Scholar
  97. 97.
    Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327: 175–181.PubMedGoogle Scholar
  98. 98.
    Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–35.Google Scholar
  99. 99.
    Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992; 19: 671–677.PubMedGoogle Scholar
  100. 100.
    Klimt CR, Knatterud GL, Stamler J, Meier P, for the PARIS II Investigator Group. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251–269.PubMedGoogle Scholar
  101. 101.
    Antiplatelet Trialist’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death myocardial infarction and stroke by prolongued antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.Google Scholar
  102. 102.
    Bleich SD, Nichols T, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412–1417.PubMedGoogle Scholar
  103. 103.
    Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433–1437.PubMedGoogle Scholar
  104. 104.
    de Bono DP, Simoons MI, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122–128.PubMedGoogle Scholar
  105. 105.
    Baird SH, McBride SJ, Trouton TG, Wilson C. Low-molecular-weight heparin versus unfractionated heparin following thrombolysis in myocardial infarction (abstract). J Am Coll Cardiol 1998; 31 (suppl. A): 191A.Google Scholar
  106. 106.
    Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328–1428.PubMedGoogle Scholar
  107. 107.
    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–677.PubMedGoogle Scholar
  108. 108.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–828.Google Scholar
  109. 109.
    Gruppo Italiano per to Studio della Sopravvivenza nell’ Infarto Miocardico. GISSI-3: effect of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–1122.Google Scholar
  110. 110.
    ISIS-4 Collaborative Group. ISIS-4: randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–685.Google Scholar
  111. 111.
    Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686–687.Google Scholar
  112. 112.
    Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary agioplasty for acute myocardial infarction. Am J Cardiol 1996; 77: 1045–1051.PubMedGoogle Scholar
  113. 113.
    Topol EJ. RAPPORT: a trial of abciximab as an adjunct to primary PTCA. Presented at the George Washington University 13th International Workshop: Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, Orlando, FL, 1997.Google Scholar
  114. 114.
    Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation 1997; 95: 846–854.PubMedGoogle Scholar
  115. 115.
    Antman EM, Giugliano RP, McCabe CH, Gibson M, Adgey AJJ, Ghali M, et al. Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: results of TIMI 14 trial (abstract). J Am Coll Cardiol 1998; 31 (suppl A): 191A.Google Scholar
  116. 116.
    Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, et al. A randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation 1998; 97: 340–349.PubMedGoogle Scholar
  117. 117.
    Cohen M, Xiong J, Parry G, Adams PC, Chamberlain D, Wieczorek I, et al. Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. J Am Coll Cardiol 1993; 22: 1338–1343.PubMedGoogle Scholar
  118. 118.
    DeBusk RF, Blomgvist CG, Kouchoukos NT, Luepker RV, Miller HS, Moss AJ, et al. Identification and treatment of low-risk patients after acute myocardial infarction and coronary bypass surgery. N Engl J Med 1986; 314: 161–166.PubMedGoogle Scholar
  119. 119.
    Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol 1995; 26: 1643–1650.PubMedGoogle Scholar
  120. 120.
    Cannon CP, McCabe CH, Stone PH, Rogers WJ, Schactman M, Thompson BW, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. J Am Coll Cardiol 1997; 30: 133–140.PubMedGoogle Scholar
  121. 121.
    Cannon CP, Sharis PJ, Schweiger MJ, McCabe CH, Diver DJ, Shah PK, et al. Prospective validation of a composite end point in thrombolytic trial of acute myocardial infarction (TIMI 4 and 5). Am J Cardiol 1997; 80: 696–699.PubMedGoogle Scholar
  122. 122.
    Mueller HS, Forman SA, Manegus MA, Cohen LS, Knatterud GL, Braunwald E, for the TIMI Investigators. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. J Am Coll Cardiol 1995; 26: 900–907.PubMedGoogle Scholar
  123. 123.
    Cannon CP. Optimizing the treatment of unstable angina. J Thromb Thrombol 1995; 2: 205–218.Google Scholar
  124. 124.
    Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987; 317: 1361–1365.PubMedGoogle Scholar
  125. 125.
    Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone P. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Harvard Atheroscleosis Reversibility Project (HARP) Group. Lancet 1994; 344: 1182–1186.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Christopher P. Cannon
  • Eugene Braunwald

There are no affiliations available

Personalised recommendations